Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study

Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (mBC). The aim of this ‘field-practice’ study was to investigate the efficacy and safety of T-DM1, focusing o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabi, Alessandra, De Laurentiis, Michelino, Caruso, Michele, Valle, Enrichetta, Moscetti, Luca, Santini, Daniele, Cannita, Katia, Carbognin, Luisa, Ciccarese, Mariangela, Rossello, Rosalba, Arpino, Grazia, Leonardi, Vita, Montemurro, Filippo, La Verde, Nicla, Generali, Daniele, Zambelli, Alberto, Scandurra, Giuseppa, Russillo, Michelangelo, Paris, Ida, D'Ottavio, Anna Maria, Filippelli, Gianfranco, Giampaglia, Marianna, Stani, Simonetta, Fabbri, Agnese, Alesini, Daniele, Cianniello, Daniela, Giannarelli, Diana, Cognetti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610019/
https://www.ncbi.nlm.nih.gov/pubmed/28969087
http://dx.doi.org/10.18632/oncotarget.16373

Ejemplares similares

Ejemplares similares